comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 16:00:39 - browse：99

President of Bayer U.S. Sebastian Guth speaks with STAT reporters at STAT's Boston headquarters, March 13, 2024 — Bayer's U.S. president, Sebastian Guth, emphasized at an interview at the STAT offices in Boston that the pharma company is no longer just focused on small molecules. Alissa Ambrose/STAT

German pharmaceutical company Bayer is expanding its U.S. pharma business significantly, despite corporate turmoil and pricing pressures that have led many in the drug industry to bemoan the potential end of the American biotech innovation boom.

Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “badly broken.”

The biggest fissure is the debt and litigation costs stemming from Bayers’s 2018 acquisition of agriculture firm Monsanto, but the aspirin-maker’s pharmaceutical portfolio is also facing strain. Some of Bayer’s top products, including the anticoagulant drug Xarelto and the eye medication Eylea, are under patent pressure. Xarelto is also one of the first drugs to be subject to Medicare price negotiations under the Inflation Reduction Act, though Johnson & Johnson owns U.S. rights to the drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： First Opinion on colorectal cancer screening: letter and response

WSS

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

UpToDate has a racism problem: Dr. Stanley Goldfarb

Mass General Brigham physicians react to latest merger step

Oral obesity drug from Viking Therapeutics hits key early target

Hundreds died while taking an arthritis drug, but nobody alerted patients

The wait for US passports is creating travel purgatory and snarling summer plans

entertainment

comprehensive

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Being 'nonadherent' patient made me a more empathetic doctor

Heart attack and stroke risk calculators need revising

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Medicare details structure of new drug price negotiation program

Bird flu in dairy cattle: New measures to control spread to humans

Virginia high school admissions case could be legal follow

U.K. decision on ALS drug has neurologists, advocates up in arms

How to save PrEP access — and even expand it

Lupron, used to halt puberty in children, may cause lasting health problems

leisure time

Bird flu reported in person exposed to presumably infected cattle

Vertex cell therapy lets patients with type 1 diabetes stop insulin

The wait for US passports is creating travel purgatory and snarling summer plans

Hundreds died while taking an arthritis drug, but nobody alerted patients

UpToDate has a racism problem: Dr. Stanley Goldfarb

Overprescribed: High cost isn't America's only drug problem

explore

hotspot

explore

knowledge